Lea Eslava-Kim, PharmD

Most Recent Articles by Lea Eslava-Kim, PharmD

Ryanodex Gets Priority Review for Exertional Heat Stroke

By Mar 27, 2017

The FDA has accepted and granted Priority Review to the New Drug Application (NDA) of Ryanodex (dantrolene sodium; Eagle) for the treatment of exertional heat stroke (EHS).

Sarecycline Promising for Moderate to Severe Acne

By Mar 27, 2017

Allergan and Paratek announced positive results from two Phase 3 studies of sarecycline for the treatment of moderate to severe acne.

Rituxan Gets Breakthrough Therapy Status for Rare Autoimmune Skin Disorder

By Mar 24, 2017

Genentech announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

Single-Dose Treatment for Bacterial Vaginosis Under Priority Review

By Mar 23, 2017

The FDA has accepted and granted Priority Review to the New Drug Application (NDA) of Solosec (secnidazole oral granules; Symbiomix) for the treatment of bacterial vaginosis (BV).

Orphan Drug Status Granted for C3 Glomerulopathy Treatment

By Mar 22, 2017

Patients with C3G experience progressive deterioration in renal function, ultimately leading to renal failure requiring dialysis and kidney transplant, if left untreated.

More Articles by Lea Eslava-Kim, PharmD